Landscape of HER2-low metastatic breast cancer (MBC): Results from the AGMT-MBC-Registry
Gampenrieder, SP; Rinnerthaler, G; Petzer, A; Tinchon, C; Fuchs, D; Balic, M; Heibl, S; Rumpold, H; Egle, D; Zabernigg, AF; Singer, CF; Andel, J; Hubalek, M; Knauer, M; Greil, R CANCER RES. 2020; 80(4):
Hospitalizations and clinical outcome in metastatic colorectal cancer during regorafenib or TAS-102 therapy
Huemer, F; Piringer, G; Schlintl, V; Hackl, H; Rinnerthaler, G; Thaler, J; Greil, R; Weiss, L ONCOL RES TREAT. 2020; 43(SUPPL 4): 128-128.
Changes in the time to adjuvant chemotherapy start over the past 10 years and correlation with outcome in early breast cancer patients
Hofer, S; De Pellegrin, L; Weiss, R; Zapf, K; Gampenrieder, SP; Hauser-Kronberger, C; Reitsamer, R; Greil, R; Rinnerthaler, G ONCOL RES TREAT. 2020; 43(SUPPL 4): 161-161.
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P plus C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Harrington, KJ; Rischin, D; Greil, R; Soulieres, D; Tahara, M; Castro, G; Psyrri, A; Baste, N; Neupane, PC; Bratland, A; Fuereder, T; Hughes, BGM; Mesia, R; Ngamphaiboon, N; Rordorf, T; Ishak, WZW; Zhang, YY; Gumuscu, B; Swaby, RF; Burtness, B J CLIN ONCOL. 2020; 38(15):
Retrospective analysis of treatment pathways in patients with BRAF(V600E)-mutant metastatic colorectal carcinoma – MORSECRC
Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Koeberle, D; Welslau, M; Akhoundova, D; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Agocs, R; Weide, R; Modest, DP; Fritsch, R ONCOL RES TREAT. 2020; 43(SUPPL 4): 131-131.
Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial
Bianchini, G; Huang, CS; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Russo, S; Ciruelos, EM; Greil, R; Semiglazov, V; Colleoni, MA; Kelly, CM; Mariani, G; Del Mastro, L; Smart, C; Valagussa, P; Viale, G; Gianni, L ANN ONCOL. 2020; 31: S1145-S1146.
Phase I study evaluating safety and tolerability of AMG 910, a half-life extended bispecific T cell engager targeting claudin-18.2 (CLDN18.2) in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma
Lordick, F; Chao, J; Buxo, E; van Laarhoven, HWM; Lima, CMR; Lorenzen, S; Dayyani, F; Heinemann, V; Greil, R; Stienen, S; Shitara, K ANN ONCOL. 2020; 31: S928-S929.
The role of Ca15-3 in the follow-up care of early breast cancer patients
Zapf, K; Weiss, R; De Pellegrin, L; Hofer, S; Rinnerthaler, G; Hauser-Kronberger, C; Reitsamer, R; Greil, R; Gampenrieder, SP ONCOL RES TREAT. 2020; 43(SUPPL 4): 162-162.
FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis
Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A ONCOL RES TREAT. 2020; 43(SUPPL 4): 215-215.
Real-world data for immune checkpoint inhibitor therapy as first line treatment of recurrent or metastatic squamous cell cancer of the head and neck
Wagner, SM; Magnes, T; Minichsdorfer, C; Gamerith, G; Pall, G; Greil, R; Melchardt, T; Fureder, T ONCOL RES TREAT. 2020; 43(SUPPL 4): 132-133.
